Dashboard
Manage Tickers

AGIO


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

the-fda-granted-orphan-drug-designation-to-agios-pharmaceuticals-tebapivat-ag-946-for-myelodysplastic-syndromes
The FDA Granted Orphan Drug Designation To...
09/11/2024 11:01:47

agios-pharmaceuticals-shares-are-trading-higher-after-the-company-announced-it-will-receive-11-billion-in-milestone-payments
Agios Pharmaceuticals shares are trading h...
08/07/2024 12:52:39

agios-to-receive-11b-milestone-payments-after-fda-approval-of-vorasidenib
Agios To Receive $1.1B Milestone Payments ...
08/06/2024 21:51:52

– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments ...

rbc-capital-maintains-outperform-on-agios-pharmaceuticals-raises-price-target-to-55
RBC Capital Maintains Outperform on Agios ...
08/02/2024 19:37:40

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price targe...

agios-pharmaceuticals-rare-blood-disorder-drug-misses-primary-goal-in-pediatric-study-stock-slides
Agios Pharmaceuticals' Rare Blood Disorder...
08/01/2024 17:42:10

Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in...

agios-pharmaceuticals-q2-2024-gaap-eps-169-misses-160-estimate-sales-8615m-miss-9307m-estimate
Agios Pharmaceuticals Q2 2024 GAAP EPS $(1...
08/01/2024 10:35:48

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate ...

agios-announces-results-from-phase-3-activate-kidst-study-of-mitapivat-in-children-with-pk-deficiency-who-are-regularly-transfused-says-prespecified-statistical-criterion-for-primary-endpoint-in-activate-kidst-was-not-met
Agios Announces Results From Phase 3 ACTIV...
08/01/2024 10:34:05

expert-ratings-for-agios-pharmaceuticals
Expert Ratings For Agios Pharmaceuticals
06/17/2024 14:01:38

cantor-fitzgerald-reiterates-overweight-on-agios-pharmaceuticals
Cantor Fitzgerald Reiterates Overweight on...
06/17/2024 13:31:59

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Overweight.

agios-announced-earlier-results-from-its--phase-3-energize-study-of-mitapivat-in-non-transfusion-dependent-thalassemia-study-achieved-its-primary-endpoint
Agios Announced Earlier Results From Its ...
06/15/2024 16:38:25

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering thera...

agio-pharmaceuticals-announces-poster-titled-improvements-in-fatigue-and-6-minute-walk-test-in-adults-with-alpha--or-beta-nontransfusion-dependent-thalassemia-the-phase-3-energize-trial-of-mitapivat
Agio Pharmaceuticals Announces Poster Titl...
06/14/2024 12:40:45

https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C

jp-morgan-reinstates-neutral-on-agios-pharmaceuticals-announces-46-price-target
JP Morgan Reinstates Neutral on Agios Phar...
06/13/2024 21:07:28

JP Morgan analyst Tessa Romero reinstates Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and announces $46 price target.

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/13/2024 17:35:22

novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio
Novavax And Agios Pharmaceuticals Were Amo...
06/09/2024 18:29:27

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

goldman-sachs-maintains-neutral-on-agios-pharmaceuticals-raises-price-target-to-53
Goldman Sachs Maintains Neutral on Agios P...
06/04/2024 15:16:38

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price targ...

rbc-capital-maintains-outperform-on-agios-pharmaceuticals-raises-price-target-to-53
RBC Capital Maintains Outperform on Agios ...
06/04/2024 13:32:11

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price targe...

why-is-agios-pharmaceuticals-stock-trading-higher-on-monday
Why Is Agios Pharmaceuticals Stock Trading...
06/03/2024 16:11:50

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-depen...

stericycle-marinemax-agios-pharmaceuticals-and-other-big-stocks-moving-higher-on-monday
Stericycle, MarineMax, Agios Pharmaceutica...
06/03/2024 14:39:44

agios-pharmaceuticals-reports-phase-3-results-for-mitapivat-in-reducing-thalassemia-transfusions
Agios Pharmaceuticals Reports Phase 3 Resu...
06/03/2024 10:32:51

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering thera...

why-applied-dna-sciences-shares-are-trading-lower-by-around-68-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Applied DNA Sciences Shares Are Tradin...
05/28/2024 17:24:16

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION